Cardiac glycoside bufalin, a potent small molecule inhibitor for SRC‐3, has been reported to strongly promote SRC‐3 protein degradation and was able to block cancer cell growth at nanomolar concentrations 22. This evidence concerns the gene NCOA3 and cancer.